MDM2- and FLT3-inhibitors in the treatment of FLT3-ITD acute myeloid leukemia, specificity and efficacy of NVP-HDM201 and midostaurin

Prognosis for FLT3-ITD positive acute myeloid leukemia with high allelic ratio (>0.5) is poor, particularly in relapse, refractory to or unfit for intensive treatment, thus highlighting an unmet need for novel therapeutic approaches. The combined use of compounds targeting both the mutated FLT3 r...

Descripción completa

Detalles Bibliográficos
Autores principales: Seipel, Katja, Marques, Miguel A.T., Sidler, Corinne, Mueller, Beatrice U., Pabst, Thomas
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Ferrata Storti Foundation 2018
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6278968/
https://www.ncbi.nlm.nih.gov/pubmed/29976747
http://dx.doi.org/10.3324/haematol.2018.191650

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6278968/
https://www.ncbi.nlm.nih.gov/pubmed/29976747
http://dx.doi.org/10.3324/haematol.2018.191650

Ejemplares similares